Rituximab therapy in nephrotic syndrome due to AH amyloidosis

• Katoh, Nagaaki

• Matsuda, Masayuki

• Miyazaki, Daigo

• Gono, Takahisa

• Yazaki, Masahide

• Ikeda, Shu-ichi

抄録

This is an electronic version of an article published in Amyloid 2009, Vol. 16, No. 3 : Pages 178-180. Amyloid is available online at: http://informahealthcare.com/doi/pdf/10.1080/13506120903090940

We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.

Article

AMYLOID. 16(3):178-180 (2009)

収録刊行物

• Amyloid-Journal of Protein Folding Disorders

  Amyloid-Journal of Protein Folding Disorders 16 (3), 178-180, 2009

  INFORMA HEALTHCARE

キーワード

• AH amyloidosis
• nephrotic syndrome
• B-cell lymphoproliferative disorder
• rituximab

詳細情報

• CRID: 1050845763844390016
• NII論文ID: 120007110405
• NII書誌ID: AA11096426
• HANDLE: 10091/11069
• ISSN: 13506129
• Web Site: https://soar-ir.repo.nii.ac.jp/records/3895
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles